Genius Sports to Announce First Quarter 2021 Results on May 20
Genius Sports Limited (NYSE:GENI) (“Genius” or “GSL”) today announced that it will release its first quarter 2021 results before 8:00AM EDT on Thursday, May 20, 2021.
At 8:00AM EDT on the same day, Genius will host a conference call to discuss the results.
Genius’ earnings press release and related materials will be available at investors.geniussports.com. To listen to the live audio webcast and Q&A, please visit Genius’ investor relations website at investors.geniussports.com. A replay of the webcast will be available on the website within 24 hours after the call.
About Genius Sports
Genius Sports is the official data, technology and commercial partner that powers the global ecosystem connecting sports, betting and media. We are a global leader in digital sports content, technology and integrity services. Our technology is used in over 150 countries worldwide, empowering sports to capture, manage and distribute their live data and video, driving their digital transformation and enhancing their relationships with fans.
We are the trusted partner to over 400 sports organizations globally, including many of the world’s largest leagues and federations such as the NFL, EPL, FIBA, NCAA, NASCAR, AFA and PGA.
Genius Sports is uniquely placed through cutting-edge technology, scale and global reach to support our partners. We are more than just a technology company, we build long-term relationships with sports at all levels, helping them to control and maximize the value of their content while providing technical expertise and round-the-clock support.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CELLTRION-HEALTHCARE12.6.2021 17:47:13 CEST | Press release
Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress
JANSSEN12.6.2021 09:03:12 CEST | Press release
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
JANSSEN12.6.2021 09:02:12 CEST | Press release
New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia
GALDERMA11.6.2021 11:55:08 CEST | Press release
Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe
SLOTS-CAPITAL11.6.2021 11:24:04 CEST | Pressemeddelelse
Slots Capital er nu tilgængelig for flere spillere end nogensinde før
SLOTS-CAPITAL11.6.2021 11:23:04 CEST | Press release
Slots Capital Available to More Players Than Ever Before
SECURE-COMMUNITIES-FORUM11.6.2021 10:17:07 CEST | Press release
Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom